Safety Pharmacology Society

Last updated
Safety Pharmacology Society
Formation2000
Headquarters Reston, Virginia
Official language
English
Current president
Marie-Luce Rosseels
Website Official website

The Safety Pharmacology Society (SPS) is a global scientific society that exists to promote 'the development and safe medical use of biologically active molecular entities" [1] for the discipline of safety pharmacology. The Society's mission statement declares that it will "lead the global safety pharmacology community in the development and safe medical use of biologically active molecular entities. We will achieve this vision by bridging across disciplines to predict, identify, characterize, monitor, and mitigate potentially undesirable pharmacodynamic activities in nonclinical studies and guiding their translation into clinical trials and beyond, to benefit all patients." [2] The Safety Pharmacology Society also supports the human safety of drugs and biologicals by fostering scientific research, education, and dissemination of scientific information through meetings and other scientific interactions.

The Safety Pharmacology Society was incorporated in 2000, [3] at the time when the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use was issuing ICH S7A, [4] a regulatory guidance covering safety pharmacology and drafting ICH S7B [5] which is more specific to potential effects of new drugs on cardiac repolarization. Prior to 2001 many of the same scientific experts met once a year in Philadelphia. [3] The historical birth of safety pharmacology is described by Alan Bass, Lewis Kinter, Patricia Williams. [6] Two of the authors, Alan Bass and Lewis Kinter, are past presidents of the Safety Pharmacology Society. [7]

The Safety Pharmacology Society is composed of members from across the globe and reaches out internationally through meetings, webinars and publications. The Society provides a number of resources that are available to members and nonmembers. The Safety Pharmacology Society also offers a certification exam, Diplomate in Safety Pharmacology (DSP). [8] The certification examination is offered online one time a year.

The key values of the SPS embrace scientific excellence, knowledge, improving human and animal life, collaboration and cooperation, integrity, quality, and respect for individual diversity, initiative, education and personal development.

The Safety Pharmacology Society organizes an annual meeting in the Fall, comprising invited speakers, posters, [9] continuing education courses and exhibits. This meeting has alternated between North America and Europe. Recent meetings have been held in:

The Safety Pharmacology Society also organizes local (regional) meetings and webinars.

Related Research Articles

<span class="mw-page-title-main">Pharmacology</span> Branch of biology concerning drugs

Pharmacology is the science of medical drugs and medications, including a substance's origin, composition, pharmacokinetics, therapeutic use, and toxicology. More specifically, it is the study of the interactions that occur between a living organism and chemicals that affect normal or abnormal biochemical function. If substances have medicinal properties, they are considered pharmaceuticals.

The Draize test is an acute toxicity test devised in 1944 by Food and Drug Administration (FDA) toxicologists John H. Draize and Jacob M. Spines. Initially used for testing cosmetics, the procedure involves applying 0.5 mL or 0.5 g of a test substance to the eye or skin of a restrained, conscious animal, and then leaving it for set amount of time before rinsing it out and recording its effects. The animals are observed for up to 14 days for signs of erythema and edema in the skin test, and redness, swelling, discharge, ulceration, hemorrhaging, cloudiness, or blindness in the tested eye. The test subject is commonly an albino rabbit, though other species are used too, including dogs. The animals are euthanized after testing if the test renders irreversible damage to the eye or skin. Animals may be re-used for testing purposes if the product tested causes no permanent damage. Animals are typically reused after a "wash out" period during which all traces of the tested product are allowed to disperse from the test site.

Certified Health Physicist is an official title granted by the American Board of Health Physics, the certification board for health physicists in the United States. A Certified Health Physicist is designated by the letters CHP or DABHP after his or her name.

Pharmacovigilance, also known as drug safety, is the pharmaceutical science relating to the "collection, detection, assessment, monitoring, and prevention" of adverse effects with pharmaceutical products. The etymological roots for the word "pharmacovigilance" are: pharmakon and vigilare. As such, pharmacovigilance heavily focuses on adverse drug reactions (ADR), which are defined as any response to a drug which is noxious and unintended, including lack of efficacy. Medication errors such as overdose, and misuse and abuse of a drug as well as drug exposure during pregnancy and breastfeeding, are also of interest, even without an adverse event, because they may result in an adverse drug reaction.

<span class="mw-page-title-main">European Medicines Agency</span> Agency of the European Union

The European Medicines Agency (EMA) is an agency of the European Union (EU) in charge of the evaluation and supervision of pharmaceutical products. Prior to 2004, it was known as the European Agency for the Evaluation of Medicinal Products or European Medicines Evaluation Agency (EMEA).

The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) is an initiative that brings together regulatory authorities and pharmaceutical industry to discuss scientific and technical aspects of pharmaceutical product development and registration. The mission of the ICH is to promote public health by achieving greater harmonisation through the development of technical Guidelines and requirements for pharmaceutical product registration.

A clinical research associate (CRA), also called a clinical monitor or trial monitor, is a health-care professional who performs many activities related to medical research, particularly clinical trials. Clinical research associates work in various settings, such as pharmaceutical companies, medical research institutes and government agencies. Depending on the jurisdiction, different education and certification requirements may be necessary, although not usually required, to practice as a clinical research associate. The main tasks of the CRA are defined by good clinical practice guidelines for monitoring clinical trials, such as those elaborated by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. A CRA would subsequently grow into a Feasibility Leader, Study Start up Leader, Project Manager, and Project Director at a Pharmaceutical company or a contract research organization. A CRA is usually required to possess an academic degree in Life Sciences and needs to have a good knowledge of good clinical practice and local regulations.

<span class="mw-page-title-main">Council for International Organizations of Medical Sciences</span> International non-governmental medical science organization

The Council for International Organizations of Medical Sciences (CIOMS) is an international non-governmental organization of 40 international, national, and associate member groups representing the biomedical science community. It was jointly established by the World Health Organization (WHO) and United Nations Educational, Scientific and Cultural Organization (UNESCO) in 1949 as a successor to the International Medical Congress that organized 17 conferences from 1867 until the 1913 outbreak of World War One.

In the experimental (non-clinical) research arena, good laboratory practice or GLP is a quality system of management controls for research laboratories and organizations to ensure the uniformity, consistency, reliability, reproducibility, quality, and integrity of products in development for human or animal health through non-clinical safety tests; from physio-chemical properties through acute to chronic toxicity tests.

<span class="mw-page-title-main">Toremifene</span> Chemical compound

Toremifene, sold under the brand name Fareston among others, is a medication which is used in the treatment of advanced breast cancer in postmenopausal women. It is taken by mouth.

The International Union of Basic and Clinical Pharmacology (IUPHAR) is a voluntary, non-profit association representing the interests of scientists in pharmacology-related fields to facilitate Better Medicines through Global Education and Research around the world.

<span class="mw-page-title-main">European Directorate for the Quality of Medicines & HealthCare</span> International organisation

The European Directorate for the Quality of Medicines & HealthCare (EDQM) is a Directorate of the Council of Europe that traces its origins and statutes to the Convention on the Elaboration of a European Pharmacopoeia.

<span class="mw-page-title-main">Michigan State University College of Natural Science</span> MSU College for the natural sciences

The College of Natural Science (NatSci) at Michigan State University is home to 27 departments and programs in the biological, physical and mathematical sciences.

Safety pharmacology is a branch of pharmacology specialising in detecting and investigating potential undesirable pharmacodynamic effects of new chemical entities (NCEs) on physiological functions in relation to exposure in the therapeutic range and above.

A glossary of terms used in clinical research.

Ali Said Faqi is a Somali scientist specializing in toxicology and a diplomat. A leading researcher in his field, he has numerous scientific papers and also authored a book entitled A Comprehensive Guide to Toxicology in Preclinical Drug Development. In 2013, he was appointed as the Somali Ambassador to Benelux and European Union.

A serenic, or antiaggressive agent, is a type of drug which reduces the capacity for irritability and aggression.

The Federation of European Pharmacological Societies (EPHAR) is a non-profit voluntary association established to advance research and education in the science of pharmacology and to promote co-operation between national/regional pharmacological societies in Europe and surrounding countries. It is an umbrella organization of currently 29 national societies for pharmacology and represents over 12,000 individual pharmacologists in Europe. Moreover it seeks to co-operate with other international organizations, especially the International Union of Basic and Clinical Pharmacology (IUPHAR) of which EPHAR is an associate member.

Guidances for statistics in regulatory affairs refers to specific documents or guidelines that provide instructions, recommendations, and standards pertaining to the application of statistical methodologies and practices within the regulatory framework of industries such as pharmaceuticals and medical devices. These guidances serve as a reference for statisticians, researchers, and professionals involved in designing, conducting, analyzing, and reporting studies and trials in compliance with regulatory requirements. These documents embody the prevailing perspectives of regulatory agencies on specific subjects. It is worth noting that in the United States, the term "Guidances" is used, while in Europe, the term "Guidelines" is employed.

<span class="mw-page-title-main">Amy O. Charkowski</span> American plant pathologist

Amy Olymbia Charkowski is an American plant pathologist and Professor of Plant Pathology at Colorado State University. She was elected Fellow of the American Association for the Advancement of Science in 2020.

References

  1. "Safety Pharmacology Society". safetypharmacology.org. Retrieved 2024-03-10.
  2. Safety Pharmacology Society (SPS). "Safety Pharmacology Society" . Retrieved August 17, 2022.
  3. 1 2 Safety Pharmacology Society (SPS). "History of Safety Pharmacology [TIMELINE]" (PDF). Retrieved 17 August 2022.
  4. ICH Harmonised Tripartite Guideline for Safety Pharmacology Studies for Human Use. ICH S7A.
  5. ICH Harmonised Tripartite Guideline for Safety Pharmacology Studies for Human Use. ICH S7B. The nonclinical evaluation of the potential for delayed ventricular repolarisation (QT interval prolongation) by human pharmaceuticals.
  6. Alan Bass, Lewis Kinter, Patricia Williams (2004) Origins, practices and future of safety pharmacology. Journal of Pharmacological and Toxicological Methods, Volume 49, Issue 3, Pages 145-151.
  7. Safety Pharmacology Society (SPS). "History" . Retrieved 17 August 2022.
  8. Authier S, Curtis MJ, Soloviev M, Redfern WS, Kallman MJ, Hamlin RL, Leishman DJ, Valentin JP, Koerner JE, Vargas HM, Botchway A, Correll K, Pugsley MK. The Diplomate in Safety Pharmacology (DSP) certification scheme. J Pharmacol Toxicol Methods. 2015 Sep-Oct;75:1-4.
  9. Redfern WS, Valentin J-P (2011) Trends in safety pharmacology: Posters presented at the annual meetings of the Safety Pharmacology Society 2001–2010. J Pharmacol. Toxicol. Methods 64: 102–110.